Cocrystal pharma's sars-cov-2 main protease inhibitors demonstrate pan-viral activity against human common coronaviruses, noroviruses, rhinoviruses, and enteroviruses

Bothell, wash., nov. 08, 2021 (globe newswire) -- cocrystal pharma, inc.  (nasdaq: cocp) (“cocrystal” or the “company”) announces that its sars-cov-2 main protease inhibitors showed potent in vitro pan-viral activity against human common coronaviruses, rhinoviruses, and respiratory enteroviruses that frequently cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis. these protease inhibitors were discovered using the company's proprietary structure-based drug discovery technology and are currently being advanced by cocrystal toward clinical development to combat sars-cov-2 and its variants.
COCP Ratings Summary
COCP Quant Ranking